NeuroSense Therapeutics Ltd.
NRSNNext catalyst
NDA Filing — PrimeC
Get an email about NRSN's next catalysts
Track NeuroSense Therapeutics (NRSN) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (NDA filing).See the timeline
2 upcoming, 0 past
NDA Filing — PrimeC
For ALS. NeuroSense Therapeutics completed the Pre-NDS process with Health Canada for its ALS drug PrimeC, with alignment achieved on submission content and structure. The company plans to file with Health Canada in December 2026.
SourceNDA Filing — PrimeC
For ALS. NeuroSense Therapeutics completed the Pre-NDS process with Health Canada for its ALS drug PrimeC, with alignment on submission content and structure ahead of a planned December 2026 filing.
SourceMarket Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
PrimeC | Phase 2 | Alzheimer Disease | - | - |
Alzheimer Disease
1 drug in this indication
ALS
1 drug in this indication
Amyotrophic Lateral Sclerosis
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in NeuroSense Therapeutics Ltd.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in NeuroSense Therapeutics Ltd.'s (NRSN) pipeline across Phase 2. Its lead program is PrimeC (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is NeuroSense Therapeutics Ltd.'s next FDA catalyst?→
NeuroSense Therapeutics Ltd.'s (NRSN) next tracked catalyst is an NDA filing expected Dec 1, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track NRSN biotech catalysts?→
Add NRSN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow NeuroSense Therapeutics Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.